Cidara Therapeutics, Inc. recently announced its receipt of a milestone payment amounting to $11.14 million from Mundipharma. This payment follows the European approval of REZZAYO, a once-weekly antifungal treatment intended for adults suffering from invasive candidiasis.
Jeffrey Stein, the President and CEO of Cidara, expressed the company's continuous commitment towards advancing their Cloudbreak platform for developing targeted immunotherapies beneficial for cancer patients, boosted by the recent milestone payment.
Cidara has already received FDA approval for REZZAYO and has licensed it to multiple partners for commercialization inside and outside the United States. For more health news, please visit rttnews.com.
